Amrutanjan Health Care Limited (AMRUTANJAN.NS)
INR 632.05
(-0.61%)
INR 632.05
(-0.61%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 621.02 Million INR | -6.63% |
| 2022 | 418.54 Million INR | -47.58% |
| 2021 | 798.4 Million INR | 11.21% |
| 2020 | 717.93 Million INR | 168.13% |
| 2019 | 267.75 Million INR | -8.78% |
| 2018 | 293.51 Million INR | 9.72% |
| 2017 | 267.52 Million INR | -19.26% |
| 2016 | 331.34 Million INR | 1.38% |
| 2015 | 326.83 Million INR | 34.39% |
| 2014 | 243.19 Million INR | 25.48% |
| 2013 | 193.8 Million INR | 25.24% |
| 2012 | 154.74 Million INR | -19.59% |
| 2011 | 192.44 Million INR | 20.75% |
| 2010 | 159.37 Million INR | -5.63% |
| 2009 | 168.89 Million INR | -6.54% |
| 2008 | 180.7 Million INR | 90.56% |
| 2007 | 94.82 Million INR | -36.26% |
| 2006 | 148.76 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 19.61 Million INR | -83.05% |
| 2023 Q4 | 115.69 Million INR | -51.31% |
| 2023 Q1 | 57.67 Million INR | -65.02% |
| 2023 FY | 390.81 Million INR | -6.63% |
| 2023 Q2 | 92.35 Million INR | 60.13% |
| 2023 Q3 | 237.6 Million INR | 157.29% |
| 2022 FY | 418.54 Million INR | -47.58% |
| 2022 Q1 | 22.62 Million INR | -88.29% |
| 2022 Q2 | 174.4 Million INR | 670.87% |
| 2022 Q3 | 145.19 Million INR | -16.75% |
| 2022 Q4 | 164.88 Million INR | 13.56% |
| 2021 Q2 | 221.4 Million INR | 62.41% |
| 2021 FY | 798.4 Million INR | 11.21% |
| 2021 Q3 | 247.46 Million INR | 11.77% |
| 2021 Q4 | 193.22 Million INR | -21.92% |
| 2021 Q1 | 136.32 Million INR | -3.17% |
| 2020 FY | 717.93 Million INR | 168.13% |
| 2020 Q1 | 66.6 Million INR | -22.64% |
| 2020 Q3 | 281.86 Million INR | 2.92% |
| 2020 Q2 | 273.85 Million INR | 311.16% |
| 2020 Q4 | 140.78 Million INR | -50.05% |
| 2019 Q3 | 103.83 Million INR | 0.73% |
| 2019 Q4 | 86.09 Million INR | -17.08% |
| 2019 Q1 | -24.08 Million INR | -112.7% |
| 2019 Q2 | 103.08 Million INR | 528.04% |
| 2019 FY | 267.75 Million INR | -8.78% |
| 2018 Q2 | 79.5 Million INR | 337.56% |
| 2018 FY | 293.51 Million INR | 9.72% |
| 2018 Q4 | 189.64 Million INR | 218.24% |
| 2018 Q3 | 59.59 Million INR | -25.05% |
| 2018 Q1 | -33.46 Million INR | -132.1% |
| 2017 FY | 267.52 Million INR | -19.26% |
| 2017 Q1 | -27.64 Million INR | -137.14% |
| 2017 Q2 | 134.78 Million INR | 587.61% |
| 2017 Q3 | 63.45 Million INR | -52.92% |
| 2017 Q4 | 104.26 Million INR | 64.32% |
| 2016 Q2 | 111.74 Million INR | 0.0% |
| 2016 FY | 331.34 Million INR | 1.38% |
| 2016 Q4 | 74.42 Million INR | -11.95% |
| 2016 Q3 | 84.52 Million INR | -24.36% |
| 2015 FY | 326.83 Million INR | 34.39% |
| 2014 FY | 243.19 Million INR | 25.48% |
| 2013 FY | 193.8 Million INR | 25.24% |
| 2012 Q4 | 67.28 Million INR | 22.82% |
| 2012 FY | 154.74 Million INR | -19.59% |
| 2012 Q2 | 50.83 Million INR | 667.0% |
| 2012 Q3 | 54.78 Million INR | 7.76% |
| 2012 Q1 | 6.62 Million INR | 0.0% |
| 2011 FY | 192.44 Million INR | 20.75% |
| 2010 FY | 159.37 Million INR | -5.63% |
| 2009 FY | 168.89 Million INR | -6.54% |
| 2008 FY | 180.7 Million INR | 90.56% |
| 2007 FY | 94.82 Million INR | -36.26% |
| 2006 FY | 148.76 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 89.215% |
| Hester Biosciences Limited | 364.77 Million INR | -70.252% |
| Aarti Drugs Limited | 7.14 Billion INR | 91.313% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 80.147% |
| Albert David Limited | 1.33 Billion INR | 53.462% |
| Alembic Limited | 767.77 Million INR | 19.113% |
| Alkem Laboratories Limited | 19.46 Billion INR | 96.809% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -161.308% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -2906.521% |
| Brooks Laboratories Limited | -72.25 Million INR | 959.529% |
| Eris Lifesciences Limited | 5.18 Billion INR | 88.015% |
| FDC Limited | 3.03 Billion INR | 79.529% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 93.084% |
| Gufic Biosciences Limited | 2.89 Billion INR | 78.539% |
| Hikal Limited | 1.49 Billion INR | 58.437% |
| Ind-Swift Limited | 1.22 Billion INR | 49.344% |
| Innova Captab Limited | 2.53 Billion INR | 75.487% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 87.434% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -190.145% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 88.032% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | 67.423% |
| Lupin Limited | 27.75 Billion INR | 97.763% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -2161.734% |
| Medico Remedies Limited | 277.11 Million INR | -124.102% |
| Morepen Laboratories Limited | 4.17 Billion INR | 85.121% |
| Nectar Lifesciences Limited | 3.89 Billion INR | 84.038% |
| Orchid Pharma Limited | 2.36 Billion INR | 73.697% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 77.709% |
| RPG Life Sciences Limited | 2.29 Billion INR | 72.908% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -198.499% |
| Sigachi Industries Limited | 1.47 Billion INR | 57.865% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 116.118% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 86.522% |
| Themis Medicare Limited | 1.3 Billion INR | 52.343% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Vaishali Pharma Limited | 6.29 Million INR | -9766.969% |
| Wanbury Limited | 1.7 Billion INR | 63.623% |
| Windlas Biotech Limited | 1.29 Billion INR | 52.188% |
| ZIM Laboratories Limited | 1.09 Billion INR | 43.446% |
| Ind-Swift Laboratories Limited | 2 Billion INR | 69.088% |
| Ipca Laboratories Limited | 29.59 Billion INR | 97.902% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.405% |
| Venus Remedies Limited | 534.65 Million INR | -16.156% |
| Sakar Healthcare Limited | 495.5 Million INR | -25.332% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 99.406% |
| Divi's Laboratories Limited | 18.31 Billion INR | 96.608% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 86.119% |
| Mankind Pharma Limited | 40.86 Billion INR | 98.48% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Laurus Labs Limited | 3.94 Billion INR | 84.272% |
| Neuland Laboratories Limited | 5.31 Billion INR | 88.322% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 91.765% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 90.449% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 98.632% |
| Wockhardt Limited | 140 Million INR | -343.591% |
| Bal Pharma Limited | 214.56 Million INR | -189.43% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.083% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 49.551% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -12.589% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 91.405% |
| Shilpa Medicare Limited | 3.76 Billion INR | 83.49% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 96.844% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -21838.014% |
| Granules India Limited | 6.52 Billion INR | 90.487% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -149.157% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 97.549% |
| NATCO Pharma Limited | 25.96 Billion INR | 97.608% |
| Suven Life Sciences Limited | -1.22 Billion INR | 150.662% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 88.116% |
| Indoco Remedies Limited | 1.52 Billion INR | 59.261% |
| Alpa Laboratories Limited | 61.51 Million INR | -909.554% |
| Lasa Supergenerics Limited | -458 Million INR | 235.594% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 115.092% |